Company Description
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States.
Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.
In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute.
The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005.
TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jan 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Charles P. Theuer M.D., Ph.D. |
Contact Details
Address: 4350 La Jolla Village Drive, Suite 800 San Diego, California 92122 United States | |
| Phone | 858-550-0780 |
| Website | traconpharma.com |
Stock Details
| Ticker Symbol | TCON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001394319 |
| CUSIP Number | 89237H209 |
| ISIN Number | US89237H2094 |
| Employer ID | 34-2037594 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Charles P. Theuer M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Scott B. Brown CPA, M.S. | Chief Financial Officer |
| Dr. James L. Freddo | Chief Medical Officer |
| Ya Huang | Executive Director of Statistical Programming |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 12, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 424B5 | Filing |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 10-K | Annual Report |